FDA Issues Draft Guidance for Accelerated Approval Confirmatory Clinical Trials
The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.
Related Articles
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Metronomic Capecitabine Improves Upon AIs in HR+/HER2- Metastatic Breast Cancer
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
Learn about cancer prevention and early detection
When it comes to cancer prevention and early detection, knowledge can be power.
Current Treatment Protocols for Ph+ ALL Treatment
Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.
Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma
An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.
Surveillance for Cutaneous Malignant Neoplasms Recommended in Post-BMT Patients – Oncology Nurse Advisor
Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.
Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma
Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
A Perspective on the MARS2 Trial
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
